This dual action could lead to more weight loss than medications targeting GLP-1
It works particularly well for researchers on moderate-dose protocols who want multiple weeks of supply from a single vial without the larger commitment (and cost) of a 30 mg vial
The number of Medicaid prescriptions and gross spending on GLP-1s have increased substantially since 2019 (Figure 2)
Chemical Name: Retatrutide (LY3437943) Classification: Triple hormone receptor agonist Mechanism: GLP-1/GIP/Glucagon receptor agonist Research Applications: Metabolic pathway research Glucose regulation mechanism studies Energy expenditure analysis Lipid metabolism research Incretin hormone pathway investigation Hepatic fat reduction studies Multi-receptor agonism research Product Specifications: Form: Lyophilized powder Purity: High purity research grade Storage: Store at -20C, protect from light and moisture Reconstitution: Use bacteriostatic water (not included) Stability: 24 months when stored properly, 30 days once reconstituted Research Background: Retatrutide is an investigational triple hormone receptor agonist that simultaneously targets GLP-1, GIP, and glucagon receptors
Also, expanding regulatory approvals for obesity indications have reinforced this segments dominance
It is a peptide similar to the hormone glucagon-like peptide-1, modified with a side chain
